Format

Send to

Choose Destination
Tuberculosis (Edinb). 2010 Nov;90(6):329-32. doi: 10.1016/j.tube.2010.06.002. Epub 2010 Jul 24.

The Achilles heel of BCG.

Author information

1
Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA. ian.orme@colostate.edu

Abstract

There have been multiple explanations put forward to try to explain the variable efficacy of the BCG vaccine. Here I propose the new hypothesis that the primary flaw of BCG is its inability to effectively establish a population of central memory T cells. Instead, the vaccine establishes immunity represented by effector memory T cells; these distribute in the lungs and may protect humans for 10-15 years but are gradually lost. With no central memory response to compensate, the individual loses any further resistance to tuberculosis. This may have serious implications for vaccine design, given the emphasis on developing recombinant forms of BCG.

PMID:
20659816
DOI:
10.1016/j.tube.2010.06.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center